We have gained a strong reputation for creating value through acquisitions and in-licensing activities – getting the most out of leading technologies by investing in further development, regulatory approvals and commercial activities.

BTG welcomes new opportunities for licensing and acquisition.

We typically look for opportunities where we can leverage our existing capabilities; providing innovative products that enable specialist physicians to serve their patients better.

We have a track record of acquisitions and licensing agreements in both Interventional Medicine and Pharmaceuticals.  These assets are sold through our established sales channels or through new sales teams supported by our existing commercial infrastructure.


In all cases we seek to maximise the value of these products by investing in development, regulatory approvals and commercial activities.

If you have a product or technology you believe BTG may be interested in, please send your enquiries to:
Charles Brigden
SVP, Head of Business Development


  • Our Strategy

    By delivering products that improve patient treatment, and that are valued by clinicians and payers, we will grow our business sustainably and deliver significant value to all our stakeholders.

    Read more
  • 05 Oct 2017

    BTG plc acquires Roxwood Medical

    BTG expands its Interventional Vascular business with the acquisition of Roxwood Medical, an innovative provider of advanced cardiovascular specialty catheters.

    Read more